Epithalon vs Selank
Both compounds are short synthetic peptides investigated in preclinical models, but the published literatures examine entirely different biological domains. Epithalon (AEDG tetrapeptide) has been studied for telomerase regulation and aging-related endpoints. Selank is a tuftsin analogue studied for GABAergic-neurotransmission modulation and anxiolytic endpoints. This page summarises the published research distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Tetrapeptide (Ala-Glu-Asp-Gly); synthetic pineal-peptide analogue | Heptapeptide; tuftsin analogue with Pro-Gly-Pro extension for protease resistance |
| Approximate molecular weight | 390.3 g/mol | 863.0 g/mol |
| Best-studied mechanism | Telomerase upregulation; telomere-length maintenance; melatonin-synthesis modulation | GABAergic-neurotransmission gene modulation; BDNF regulation; cytokine-profile effects |
| Primary research domain | Aging biology, telomere research, carcinogenesis, neurogenesis | CNS: anxiolytic endpoints, cognitive function, neuroimmunology |
| Common research routes | Intraperitoneal, intranasal | Intranasal, intraperitoneal |
| Reconstitution practice | Bacteriostatic water; lyophilised vial | Bacteriostatic water; lyophilised vial |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
Epithalon (AEDG tetrapeptide) has been investigated for telomerase-upregulation activity. The published literature describes telomere-length maintenance in human cell lines, lifespan extension in Drosophila, carcinogenesis inhibition in rodent models, and neurogenesis-related gene-expression stimulation. The mechanistic frame centres on aging biology and cellular senescence pathways.
Selank is a tuftsin analogue with a Pro-Gly-Pro C-terminal extension for protease resistance. Published mechanistic work describes modulation of GABAergic-neurotransmission gene expression, BDNF and trkB regulation in hippocampal and cortical tissue, and cytokine-profile changes under stress conditions. The research domain is CNS pharmacology and neuroimmunology.
The two compounds have no mechanistic intersection. Epithalon operates in aging biology and telomere science. Selank operates in neuroscience and immunomodulation. A researcher reading both is reading entirely separate bodies of work.
How research has examined each
The epithalon literature includes lifespan studies (Khavinson, 2000), carcinogenesis inhibition (Anisimov, 2002; Kossoy, 2006), neurogenesis gene expression (Khavinson, 2020), oocyte-aging protection (Yue et al., 2022), and telomere-length characterisation (Al-Dulaimi, 2025). The lead research community is gerontology and pineal-peptide biology.
The selank literature includes GABAergic gene expression (Volkova, 2016), BDNF regulation (Dolotov, 2006; Kolik, 2019), morphine-withdrawal attenuation (Konstantinopolsky, 2022), and stress-related behavioural endpoints. The lead research community is behavioural pharmacology and neuroimmunology.
The two literatures share no primary citations, model systems, or lead authors. The only categorical overlap is the broad ‘research peptide’ classification in survey reviews.
Stacking considerations in research contexts
Combined administration of epithalon and selank is not described in published research. The mechanisms (telomerase regulation versus GABAergic modulation) are entirely unrelated. Both compounds are sold as separate 10 mg lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds ship as 10 mg lyophilised peptide in glass vials with certificate-of-analysis documentation. The Epithalon vial page and the Selank vial page carry per-compound spec sheets. Both are research-grade reagents.
Frequently asked research questions
Are epithalon and selank related?
No. Epithalon is a pineal-derived tetrapeptide studied for telomere biology. Selank is a tuftsin-derived heptapeptide studied for GABAergic modulation. Unrelated sequences and mechanisms.
Do they target the same domain?
No. Epithalon is in aging-biology research. Selank is in CNS pharmacology and neuroimmunology.
Are they stacked?
Not in published research.
Do they share storage practice?
Yes. Both are lyophilised peptides stored at 2-8 degrees Celsius.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents.
References
- Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 2000. [PMID 11087911]
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016. [PMID 26924987]
- Kolik LG et al. Selank protects against ethanol-induced memory impairment by regulating BDNF content. Bulletin of Experimental Biology and Medicine, 2019. [PMID 31625062]
- Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 2025. [PMID 40141333]
- Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines. Biogerontology, 2025. [PMID 40908429]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.